ArticleAmerican journal of translational research2025
Radiomic analysis of multiple MRI sequences for diagnosing liver cancer vs. focal nodular hyperplasia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and validate a radiomics model that uses multiple magnetic resonance imaging (MRI) sequences to accurately distinguish hepatocellular carcinoma (HCC) from focal nodular hyperplasia (FNH), thereby improving diagnostic precision and decision-making.
methodsWe conducted a retrospective analysis including 196 patients (97 in HCC and 99 in FNH) diagnosed at the Zhangzhou Affiliated Hospital of Fujian Medical University (August 2011-December 2021). Radiomics features were extracted from the MRI images. LASSO logistic regression models were constructed for feature selection and to differentiate HCC from FNH. The model was further validated using a temporally independent cohort of 91 patients (49 HCC, 42 FNH) from the same institution (January 2022-December 2023). The area under the curve (AUC), accuracy, sensitivity, and specificity were used to evaluate the model's performance.
resultsWe obtained 34 features for T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and contrast enhanced imaging (CEI). The radiomics model demonstrated high diagnostic performance, with AUCs of 0.992 and 0.958 in the training and internal validation, respectively. In the independent external validation set, the model maintained strong performance with an AUC of 0.903, sensitivity of 88.9%, and specificity of 87.2%. In the training and internal validation, the model also showed high accuracy (0.956 and 0.867, respectively) and sensitivity (0.957 and 0.900, respectively). The integrated T2WI + DWI + CEI (TDC)-clinical data model demonstrated higher diagnostic accuracy than the TDC-only model.
conclusionThe developed multimodal MRI radiomics model effectively differentiated HCC from FNH and offers a non-invasive diagnostic tool that surpasses traditional imaging techniques. Further research is warranted to confirm these findings and explore the model's applications in broader clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.